IP Library Granted Patent US 11,220,718
Granted Patent B2
US 11,220,718 · App. 16/892,132 · Granted Jan 11, 2022

Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences

Inventors: Ronaldus Adrianus Maria Fouchier (Rotterdam, NL); Bernadetta Gerarda Van Den Hoogen (Rotterdam, NL); Albertus Dominicus Marcellinus Erasmus Osterhaus (Bunnik, NL); Jan Cornelius De Jong (Gouda, NL); Jan Groen (Hilversum, NL)
Assignee: Erasmus University Medical Center Rotterdam
C12Q1/701A61K39/12A61K39/155C07K14/005C07K16/1027C12N7/00C12N15/86G01N33/502G01N33/5008G01N33/5011G01N33/5088G01N33/56983A61K2039/5254A61K2039/5256A61K2039/545A61K2039/552A61K2039/58A61K2039/70A61K2123/00C12N2710/22034C12N2760/18321C12N2760/18322C12N2760/18334C12N2760/18343C12N2760/18522C12N2760/18534C12N2760/18621C12N2760/18622C12N2760/18634C12N2760/18643C12N2840/203C12Q2600/158G01N2333/08Y02A90/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,220,718
App. No.
16/892,132
Granted
Jan 11, 2022
Kind
B2
Abstract

Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

Claims (26)

1. A kit for determining the presence of metapneumovirus (MPV) in a mammalian subject, the kit comprising:

a DNA probe of at least 10 nucleotides that specifically hybridizes to a target polynucleotide,

wherein the DNA probe does not specifically hybridize to a polynucleotide from avian pneumovirus (APV);

wherein the probe does not hybridize under stringent conditions to a sequence encoding a polypeptide of SEQ ID NOs:378 and 380 or the complement of the sequence;

wherein the stringent conditions include a hybridization buffer comprising 6×SSC and 1 mM EDTA; and

wherein the target polynucleotide comprises a first nucleic acid encoding a polypeptide that is at least 90% identical to SEQ ID NO:379 or the complement of the first nucleic acid; or

wherein the target polynucleotide comprises a second nucleic acid encoding a polypeptide that is at least 90% identical to SEQ ID NO:381 or the complement of the second nucleic acid.

2. The kit of claim 1 , wherein the DNA probe comprises at least 25 nucleotides.

3. The kit of claim 1 , wherein the DNA probe comprises at least 40 nucleotides.

4. The kit of claim 1 , wherein the DNA probe further comprises a detectable marker.

5. The kit of claim 1 , wherein the target polynucleotide comprises a nucleic acid encoding SEQ ID NO:375 or wherein the target polynucleotide comprises a nucleic acid encoding SEQ ID NO:377.

6. A method for detecting metapneumovirus (MPV) subtype A2 or B2 in a mammalian subject, the method comprising:

contacting a sample from the subject with a probe nucleic acid of at least 10 nucleotides that hybridizes under stringent conditions to a sequence encoding a polypeptide that is at least 90% identical to one of SEQ ID NOs:379 and 381 or the complement of the sequence; and

detecting hybridization of the probe and the target polynucleotide;

wherein the probe does not hybridize under stringent conditions to a sequence encoding a polypeptide of SEQ ID NOs: 378 and 380 or the complement of the sequence; and

wherein the stringent conditions include a hybridization buffer comprising 6×SSC and 1 mM EDTA.

7. The method according to claim 6 , wherein the probe nucleic acid comprises at least 25 nucleotides.

8. The method according to claim 6 , wherein the probe nucleic acid comprises at least 40 nucleotides.

9. The method according to claim 6 , wherein detecting hybridization of the probe and the target polynucleotide comprises performing PCR with the probe nucleic acid as a primer.

10. The method according to claim 6 , wherein the mammalian subject is a human.

11. The method according to claim 6 , wherein the probe nucleic acid comprises a detectable marker.

12. The method according to claim 6 , wherein the probe is attached to a solid support.

13. The method according to claim 6 , wherein the target polynucleotide comprises a nucleic acid encoding one of SEQ ID NOs: 375 and 377.

14. The method according to claim 6 , wherein the target polynucleotide comprises the complement of a nucleic acid encoding one of SEQ ID NOs: 375 and 377.

15. The method according to claim 6 , the method further comprising:

diagnosing the subject as infected with MPV based on the hybridization of the probe to the target polynucleotide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2020
From: VIRONOVATIVE BV
To: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
Reel/Frame 052831/0378 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2020
From: FOUCHIER, RONALDUS ADRIANUS MARIA; VAN DEN HOOGEN, BERNADETTA GERARDA; OSTERHAUS, ALBERTUS DOMINICUS MARCELLINUS ERASMUS; DE JONG, JAN CORNELIUS; GROEN, JAN
To: VIRONOVATIVE BV
Reel/Frame 052831/0381 →
Continuity (9)
Continuation 16392234 · Apr 23, 2019
Continuation 15940432 · Mar 29, 2018
Continuation 15804585 · Nov 6, 2017
Continuation 15404854 · Jan 12, 2017
Continuation 14460285 · Aug 14, 2014
Continuation 12284347 · Sep 18, 2008
Continuation 10371099 · Feb 21, 2003
Provisional Application 60358934 · Feb 21, 2002
Related Publication 20200399718A1 · Dec 24, 2020